FDA approved Pfizer-BioNTech’s XFG-adapted COMIRNATY formula for adults 65 and older and high-risk people aged 5 to 64 years.
News|Articles|September 12, 2022
COVID-19 Update: US Vaccinations, Booster Doses, & Global Data as of September 12, 2022
Author(s)Sydney Jennings
Advertisement
US COVID-19 vaccination & booster dose status
US COVID-19 vaccination status according to the Centers for Disease Control and Prevention (CDC) as of September 8, 2022, at 6:00 AM, EDT:
Fully vaccinated plus 2 booster doses:
• Aged ≥50 years 34.3%
• Aged ≥65 years 41.5%
Fully vaccinated plus 1 booster dose:
• Total US population 48.6%
Fully vaccinated in key age groups:
• Total US population 67.6%
• Aged ≥5 years 71.7%
• Aged ≥65 years 92.1%
US confirmed cases of COVID-19 and deaths
Confirmed US cases of COVID-19 and related deaths according to the Johns Hopkins COVID-19 interactive map , as of September 12, 2022 at 3:21 PM, EDT.
3 states with highest number of new cases in past 28 days
• California 252 131
• Texas 220 564
• Florida 159 715
• Total US confirmed cases 95 297 288
• Total US confirmed deaths 1 050 475
Global total COVID-19 confirmed cases, deaths, vaccine doses administered:
• Cases 608 915 521
• Deaths 6 515 192 • Vaccine doses administered 12 199 588 001
Advertisement
Related to this article
A Vaccine Integrity Project review found influenza, COVID-19, and RSV immunizations continue to protect against severe illness, hospitalization, and death.
Pre-existing antibodies to common microbes predicted COVID-19 vaccine response strength in healthy and immunosuppressed adults.
Catch up on the 9 FDA drug approvals most relevant to primary care, including new options for HIV-1 infection, narcolepsy, diabetes, pain management, and more.
FDA approved bictegravir/lenacapavir for adults with suppressed HIV-1 and no known or suspected component resistance.
FDA expands dolutegravir dispersible tablets to children with HIV-1 weighing at least 2 kg, including eligible term newborns.
The CardioGuide HF app from Abbott will show patients their pulmonary artery pressure trends and deliver medication instructions set by their care teams.
FDA has granted IDE approval for the STROKE-REWIRE pivotal trial evaluating NeuWire Medical's neurostimulation device for chronic ischemic stroke recovery.
Advertisement
Advertisement
Trending on Patient Care Online
1
9 Drugs Approved for Primary Care: Q3 2026
2
Abbott Gains FDA Approval for CardioMEMS Update Letting Heart Failure Patients View Pressure Readings on Their Phones
3
Immunizing Against Pain and Fear: Rethinking the Vaccination Experience
4
FDA Clears IDE for NeuWire Medical's STROKE-REWIRE Trial in Chronic Ischemic Stroke
5